Cellular Dynamics International, ACEA Biosciences, Inc., and Roche Applied Science Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System

PENZBERG, Germany--(BUSINESS WIRE)--Cellular Dynamics International (CDI) announced today their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process. The partnership combines CDI’s induced pluripotent stem cell (iPSC)-derived heart cells, iCell Cardiomyocytes, with the xCELLigence RTCA System. The xCELLigence System is developed by ACEA and Roche Applied Science (SIX:RO) (SIX:ROG) (Pink Sheets:RHHBY) and marketed by Roche.